Michal Jerzy Walczak
Chief Tech/Sci/R&D Officer at CAPTOR THERAPEUTICS SPOLKA AKCYJNA
Network origin in Michal Jerzy Walczak first degree
Entity | Entity type | Industry | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 9 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Michal Jerzy Walczak via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
NESTLÉ S.A. | Food: Major Diversified | Corporate Officer/Principal | |
OT LOGISTICS S.A. | Other Transportation | Corporate Officer/Principal | |
Santander Towarzystwo Funduszy Inwestycyjnych SA
Santander Towarzystwo Funduszy Inwestycyjnych SA Investment ManagersFinance Santander Towarzystwo Funduszy Inwestycyjnych SA (Santander TFI), formerly known as BZ WBK TFI SA, is the Polish fund management subsidiary of Santander Bank Polska SA (WSE: SPL) in Poland. Headquartered in Poznan, Santander TFI SA specializes in equity and fixed income investments, manages investment funds and separate accounts for institutions, pension funds and private individuals. | Investment Managers | President | |
PKO TFI SA
PKO TFI SA Investment ManagersFinance PKO TFI SA is the fund management subsidiary of Powszechna Kasa Oszczednosci Bank Polski SA (WSE: PKO) in Poland. Headquartered in Warsaw, the firm was established by PKO Bank Polski and Swiss financial group Credit Suisse in 1997 to provide a variety of funds and investment schemes, available via their distribution network across Poland for individual and institutional clients. | Investment Managers | Analyst-Equity | |
University of Strathclyde | College/University | Doctorate Degree | |
Novartis Venture Funds
Novartis Venture Funds Investment ManagersFinance Novartis Venture Funds (NVF) is a venture capital firm with headquarters in Basel, Switzerland and an additional office in Cambridge, MA. The firm was founded in 1996. NVF is a subsidiary of Novartis AG (VX: NOVN) and was created following the 1996 merger of Ciba-Geigy and Sandoz. | Investment Managers | Chief Investment Officer | |
The State University of New York | College/University | Undergraduate Degree | |
NEOVACS | Pharmaceuticals: Major | Director/Board Member | |
Warsaw School of Economics | College/University | Masters Business Admin Graduate Degree Undergraduate Degree | |
University of Warsaw | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
PKP CARGO S.A. | Marine Shipping | Director of Finance/CFO | |
Altimmune UK Ltd.
Altimmune UK Ltd. BiotechnologyHealth Technology Altimmune UK Ltd. engages in the discovery and development of prophylactic and therapeutic vaccines against mutating viruses and cancer. It provides T-cell vaccines to protect patients against infectious diseases (most notably mutating viruses) and to treat cancers; and Flunisyn, a DepoVaccine to protect against influenza. The company was founded by Bertrand Georges in 2003 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Director/Board Member | |
Okairos AG
Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
MERUS N.V. | Biotechnology | Director/Board Member | |
binx health, inc.
binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom. | Information Technology Services | Director/Board Member | |
MyoPowers Medical Technologies France SAS
MyoPowers Medical Technologies France SAS Medical SpecialtiesHealth Technology MyoPowers Medical Technologies France SA operates as a medical device company. It specializes in muscle technologies to restore or improve muscle function. The firm also develops implantable medical devices for the treatment of severe stress urinary incontinence. The company was founded by Piergiorgio Tozzi and Daniel Hyoz in June 2004 and is headquartered in Lausanne, Switzerland. | Medical Specialties | Director/Board Member | |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
Politechnika Wroclawska | College/University | Doctorate Degree | |
GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member | |
Anokion SA
Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member | |
PKP Cargo Connect Sp zoo
PKP Cargo Connect Sp zoo Other TransportationTransportation PKP Cargo Connect Sp zoo engages in the provision of logistics services. It offers train and truck forwarding, sea and air freight arrangements, ferry shipments between Poland and Scandinavia, transport of oversize and heavy loads, customs services, warehousing logistics, transshipment terminals, and other logistics and transportation services. The company was founded in 1990 and is headquartered in Warsaw, Poland. | Other Transportation | Corporate Officer/Principal | |
Warsaw University of Technology Business School | College/University | Graduate Degree | |
Kanyos Bio, Inc.
Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member | |
Adicet Therapeutics, Inc.
Adicet Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA. | Pharmaceuticals: Major | Director/Board Member | |
École Supérieure de Biothechnologie Strasbourg | College/University | Graduate Degree | |
STK SA
STK SA Other TransportationTransportation STK SA operates as a railway operator company. It specializes in transportation of fuels and chemicals, cargoes, and rolling stock, training of the train drivers and railway staff, and repair works in the scope of ongoing handling and diagnostics of electric and diesel locomotives. The company was founded in 2005 and is headquartered in Wroclaw, Poland. | Other Transportation | Director/Board Member | |
Oculis SA
Oculis SA Miscellaneous Commercial ServicesCommercial Services Oculis SA focuses on ophthalmic drugs and novel drug delivery to the eye. The Oculis drug delivery platform consists of a novel technique to facilitate drug absorption to both anterior and posterior parts of the eye. The advantage is a drug delivery system where diseases of the posterior part of the eye can be treated with a simple topical application. The Oculis drug delivery platform allows diseases such as DME (diabetic macular edema) at the posterior part of the eye to be treated with a non-invasive topical application. The company was founded by Einar Stefansson and Thorsteinn Loftsson in 2003is headquartered in Pully, Switzerland. | Miscellaneous Commercial Services | Chairman | |
Inflazome Ltd.
Inflazome Ltd. Pharmaceuticals: MajorHealth Technology Inflazome Ltd. engages in developing therapeutic medicines for inflammatory diseases. It manufactures and supplies medicines for muckle wells, type 2 diabetes, atherosclerosis, hypertension, gout, osteoarthritis, rheumatoid arthritis, Parkinson, Alzheimer, and multiple sclerosis. The company was founded by Matthew A. Cooper and Luke O'Neill in 2016 and is headquartered in Dublin, Ireland. | Pharmaceuticals: Major | Director/Board Member | |
Imcheck Therapeutics SAS
Imcheck Therapeutics SAS Pharmaceuticals: MajorHealth Technology Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France. | Pharmaceuticals: Major | Director/Board Member | |
Vivet Therapeutics SAS
Vivet Therapeutics SAS BiotechnologyHealth Technology Vivet Therapeutics SAS develops novel gene therapy treatments for inherited metabolic diseases. The firm offers its services under the categorizers of Biopharma, Biotechnology and Health Care. The company was founded by Jean-Philippe Combal, Gloria Gonzalez-Aseguinolaza and Jens Kurth on July 26, 2016 and is headquartered in Paris, France. | Biotechnology | Chairman | |
SCANWAY S.A. | Electronic Equipment/Instruments | Director/Board Member | |
Pkp Cargo Connect GmbH | Corporate Officer/Principal | ||
Priothera Ltd.
Priothera Ltd. BiotechnologyHealth Technology Priothera Ltd. engages in the development of orally delivered sphingosine-1-phosphate (S1P) receptor modulators for hematological malignancies. The company was founded by Florent Gros, Shaval Patel, and Brice Suire in 2020 and is headquartered in Dublin, Ireland. | Biotechnology | Chief Executive Officer | |
Neurophoenix SAS | Chief Executive Officer | ||
Tom Shepherd Consulting SAS | Chairman | ||
Denovo Solutions Sp zoo | Corporate Officer/Principal | ||
Swissvention Partners GmbH | Chief Executive Officer | ||
Amyl Therapeutics SRL
Amyl Therapeutics SRL BiotechnologyHealth Technology Amyl Therapeutics SRL is a Belgian biotech company that uses a novel mechanism to bind to the amyloid fold of toxic protein aggregates of various types, including antibody light chain (AL) or transthyretin (TTR) aggregates, which accumulate in peripheral organs to cause systemic amyloidosis diseases, but also amyloid-? (A?), tau, and ?-synuclein aggregates, which accumulate in the brain to cause Alzheimer's and Parkinson's diseases. Amyl Therapeutics is based in Liege, BE and was founded in November 2020 by Drs. The company's therapies based on the clarity technology platform are designed to prevent the further accumulation of aggregates and clear existing aggregates from the peripheral organs and the brain, while also blocking further cell-to-cell spread of misfolded proteins. Florent Gros and Pierre Vandepapelière. Pierre Vandepapelière has been the CEO since incorporation. | Biotechnology | Founder | |
Priothera SAS
Priothera SAS BiotechnologyHealth Technology Part of Priothera Ltd., Priothera SAS is a French company dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of both allogeneic hematopoietic stem cell transplantation (HSCT) and CAR-T cell therapy. The company is based in Saint-Louis, France. Priothera is leading the way in developing Mocravimod, a S1P receptor modulator as an adjunctive and maintenance immune therapy to allo-HSCT and to CAR-T. Mocravimod has the potential to reduce the occurrence of (acute) GVHD without suppressing T cell function, thus GVL is maintained. Priothera is developing Mocravimod (KRP203) to significantly improve the clinical outcome of allo-HSCT and CAR-T therapy. The company was founded in 2020 by Philippe Lievre, Florent Gros, Brice R. Suire, Stephan Oehen, Simone Seiter. Florent Gros has been the CEO since 2020. | Biotechnology | Chief Executive Officer | |
Third Dot
Third Dot Investment ManagersFinance Third Dot provides investment advice. The private company is based in Warsaw, Poland. The Polish company was founded by Andrzej Bernatowicz. | Investment Managers | Portfolio Manager-Equities | |
Kozminski University | College/University | Graduate Degree |
Statistics
International
Poland | 16 |
France | 11 |
Switzerland | 7 |
United States | 6 |
Ireland | 4 |
Sectoral
Health Technology | 20 |
Consumer Services | 9 |
Transportation | 5 |
Finance | 5 |
Health Services | 3 |
Operational
Director/Board Member | 24 |
Chief Executive Officer | 8 |
Undergraduate Degree | 8 |
Corporate Officer/Principal | 7 |
Chairman | 5 |
Most connected contacts
- Stock Market
- Insiders
- Michal Jerzy Walczak
- Company connections